Cargando…

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study

BACKGROUND: Hepatitis C is curable with direct-acting antivirals (DAAs). However, treatment uptake remains low among marginalized populations such as people who inject drugs. We sought to understand challenges to treatment uptake with DAAs among people living with hepatitis C and compare treatment e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antoniou, Tony, Pritlove, Cheryl, Shearer, Dana, Tadrous, Mina, Shah, Hemant, Gomes, Tara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243011/ https://www.ncbi.nlm.nih.gov/pubmed/37280588 http://dx.doi.org/10.1186/s12939-023-01924-4

Ejemplares similares

Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada
por: Chu, Cherry, et al.
Publicado: (2023)

Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase
por: Hayes, Kaleen N., et al.
Publicado: (2021)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals
por: Yoo, Eric R., et al.
Publicado: (2017)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
por: Wong, Yu Jun, et al.
Publicado: (2021)

Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis
por: Shakeri, Ahmad, et al.
Publicado: (2021)

Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
por: Westermann, Claudia, et al.
Publicado: (2018)

Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents
por: Westermann, Claudia, et al.
Publicado: (2021)

Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infection
por: Sackey, Bryan, et al.
Publicado: (2018)

Access to hepatitis C medicines
por: Edwards, Danny J, et al.
Publicado: (2015)

Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection
por: Salama, Iman Ibrahim, et al.
Publicado: (2022)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients
por: Al-Busafi, Said A., et al.
Publicado: (2017)

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C
por: Lin, Sheng Feng, et al.
Publicado: (2020)

High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study
por: Yee, Jasmine, et al.
Publicado: (2021)

The epidemiology of benzodiazepine-related toxicity in Ontario, Canada: a population-based descriptive study
por: Campbell, Tonya J., et al.
Publicado: (2023)

Development of Autoimmune Hepatitis during Direct-acting Antiviral Therapy for Chronic Hepatitis C Virus Infection
por: Matsumoto, Kotaro, et al.
Publicado: (2018)

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis
por: Simoes, Camila C., et al.
Publicado: (2019)

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C
por: Zaimi, Yosra, et al.
Publicado: (2021)

Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals
por: Alswat, Khalid, et al.
Publicado: (2022)

Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
por: Niu, Bin, et al.
Publicado: (2023)

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
por: Adiwijaya, Bambang S., et al.
Publicado: (2012)

Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study
por: Machado, Soraia M., et al.
Publicado: (2020)

Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals
por: Nevola, Riccardo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fdj02e13uv2v8iuqv4kl3u2pcs